Abstract
The 12/15-lipoxygenase (12/15LO) enzyme is widely distributed within the central nervous system. Previous work showed that this protein is upregulated in Alzheimer’s disease (AD), and plays an active role in the development of brain amyloidosis in amyloid beta (Aβ)-precursor protein transgenic mice (Tg2576). In the present paper, we studied the effect of its pharmacologic inhibition on the AD-like phenotype of a mouse model with plaques and tangles, the triple-transgenic mice. Compared with mice receiving placebo, the group treated with PD146176, a specific 12/15LO inhibitor, manifested a significant improvement of their memory deficits. The same animals had a significant reduction in Aβ levels and deposition, which was secondary to a decrease in the β-secretase pathway. In addition, while total tau-soluble levels were unchanged for both groups, PD146176-treated mice had a significant reduction in its phosphorylation state and insoluble fraction, which specifically associated with decrease in stress-activated protein kinase/c-Jun N-terminal kinase activity. In vitro study showed that the effect on tau and Aβ were independent from each other. These data establish a functional role for 12/15LO in the pathogenesis of the full spectrum of the AD-like phenotype and represent the successful completion of the initial step for the preclinical development of 12/15LO inhibitors as novel therapeutic agents for AD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Feinmark SJ, Begum R, Tsvetkov E, Goussakov I, Funk CD, Siegelbaum SA et al. 12-Lipoxygenase metabolites of arachidonic acid mediate metabotropic glutamate receptor-dependent Long-Term depression at hippocampal CA3–CA1 synapses. J Neurosci 2003; 23: 11427–11435.
Li Y, Maher P, Schubert D . A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 1997; 19: 453–463.
Lebeau A, Terro F, Rostene W, Pelaprat D . Blockade of 12-lipoxygenase expression protects cortical neurons from apoptosis induced by beta-amyloid peptide. Cell Death Differ 2004; 11: 875–884.
Chinnici C, Yao Y, Funk C, Praticò D . Absence of 12/15 lipoxygenase reduces brain oxidative stress in apolipoprotein E-deficient mice. Am J Pathol 2005; 167: 1371–1377.
Praticò D, Zhukareva V, Yao Y, Uryu K, Funk CD, Lawson JA et al. 12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am J Pathol 2004; 164: 1655–1662.
Yao Y, Clark CM, Trojanowski JQ, Lee VM, Pratico D . Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol 2005; 58: 623–626.
Yang H, Zhuo J, Chu J, Chinnici C, Praticò D . Amelioration of the Alzheimer’s disease phenotype by absence of 12/15-lipoxygenase. Biol Psychiatry 2010; 68: 922–929.
Chu J, Zhuo JM, Praticò D . Transcriptional regulation of β-secretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments. Ann Neurol 2012; 71: 57–67.
Oddo A, Caccamo A, Shepherd JD, Murphy MP, Golde T, Kayed R et al. Triple transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409–421.
Succol F, Praticò D . A role for 12/15 lipoxygenase in the amyloid β precursor protein metabolism. J Neurochem 2007; 103: 380–387.
Joshi YB, Chu J, Praticò D . Stress hormone leads to memory deficits and altered tau phosphorylation in a model of Alzheimer’s disease. J Alzheimers Dis 2012; 31: 167–176.
Giannopoulos PF, Chu J, Joshi Y, Sperow M, Kirby LG, Praticò D . Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple transgenic model of Alzheimer’s disease. Mol Psychiatry 2014; 19: 511–518.
Chu J, Praticò D . 5-Lipoxygenase as an endogenous modulator of amyloid beta formation in vivo. Ann Neurol 2011; 69: 34–46.
Giannopoulos PF, Joshi YB, Chu J, Praticò D . The 12/15-lipoxygenase is a modulator of Alzheimer's-related tau pathology in vivo. Aging Cell 2013; 12: 1082–1090.
Giannopoulos PF, Joshi YB, Praticò D . Novel lipid signaling pathways in Alzheimer disease pathogenesis. Biochem Pharmacol 2014; 88: 560–564.
Sendobry SM, Cornicelli JA, Welch K, Bocan T, Tait B, Trivedi BK et al. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br J Pharmacol 1997; 120: 1199–1206.
Gong CX, Iqbal K . Hyper-phosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 2008; 15: 2321–2328.
Martin L, Latypova X, Terro F . Post-translational modifications of tau protein: implications for Alzheimer’s disease. Neurochem Int 2011; 58: 458–471.
DeKosky ST, Scheff SW . Synaptic loss in frontal cortex biopsies in Alzheimer’s disease correlation with cognitive severity. Ann Neurol 1990; 27: 457–464.
Sahara N, Maeda S, Takashima A . Tau oligomerization: a role for tau aggregation intermediates linked to neurodegeneration. Curr Alzheimer Res 2008; 5: 591–598.
Atzori C, Ghetti B, Piva R, Srinivasan AN, Zolo P, Delisle MB et al. Activation of JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 2001; 60: 1190–1197.
Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW . Activation of c-Jun N-terminal kinase and p38 in an Alzheimer’s disease model is associated with amyloid deposition. J Neurosci 2002; 22: 3376–3385.
Sun W, Qureshi HY, Cafferty PW, Sobue K, Agarwal-Mawal A, Neufield KD et al. Glycogen synthase kinase-beta is complexed with tau protein in brain microtubules. J Biol Chem 2002; 277: 11933–11940.
Liu SJ, Zhang AH, Li HL, Wang Q, Deng HM, Netzer WJ et al. Over-activation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem 2003; 87: 1333–1344.
Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH . Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3β. J Neurochem 2000; 74: 1587–1595.
Planel E, Miyasaka T, Launey T, Chui D, Tanemura K, Sato S et al. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer’s disease. J Neurosci 2004; 24: 2401–2411.
Ferrer I, Barrachina M, Puig B . Anti-tau phospho-specific Ser262 antibody recognizes a variety of abnormal hyper-phosphorylated tau deposits in tauopathies including Pick bodies and argyrophilic grains. Acta Neuropathol 2002; 104: 658–664.
Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H et al. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 2001; 76: 435–441.
Masliah E, Mallory M, Alford M, De Teresa R, Hansen LA, McKeel DW et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease. Neurology 2001; 56: 127–129.
Joshi YB, Praticò D . Neuroinflammation and Alzheimer’s disease: lessons learned from the 5-lipoxygenase. Transl Neurosci 2014; 5: 197–202.
Oddo S, Caccamo A, Tseng B, Cheng D, Vasilevko V, Cribbs DH et al. Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci 2008; 28: 12163–12175.
Acknowledgements
This work was in part supported by a grant from the Alzheimer’s Art Quilt Initiative. We would like to thank Dr Peter Davis for the generous gift of the PHF-1 antibody used in the study.
Author Contributions
JC and DP designed the study, developed the experimental design, performed data analysis and wrote the paper. JC, J-GL, PFG and BEB performed the experiment. BEB, WC and MA-G were involved in the synthesis of PD146176 and assessment of pharmacological effect on the enzyme activity. All the authors discussed the results and commented on the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Molecular Psychiatry website
Supplementary information
Rights and permissions
About this article
Cite this article
Chu, J., Li, JG., Giannopoulos, P. et al. Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Aβ and tau neuropathology in the triple-transgenic mice. Mol Psychiatry 20, 1329–1338 (2015). https://doi.org/10.1038/mp.2014.170
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/mp.2014.170
This article is cited by
-
Dexmedetomidine prevents spatial learning and memory impairment induced by chronic REM sleep deprivation in rats
Sleep and Biological Rhythms (2023)
-
Neurochemical Research of LOXBlock-1 and ZnSO4 against Neurodegenerative Damage Induced by Amyloid Beta(1-42)
Biological Trace Element Research (2023)
-
A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes
Nature Communications (2022)
-
Iron and Ferroptosis as Therapeutic Targets in Alzheimer's Disease
Neurotherapeutics (2021)
-
Tau-based therapies in neurodegeneration: opportunities and challenges
Nature Reviews Drug Discovery (2017)